期刊文献+

间变性淋巴瘤激酶酪氨酸激酶抑制剂布格替尼的药理作用与临床评价 被引量:4

Pharmacological and clinical evaluation of brigatinib——an anaplastic lymphoma kinase tyrosine kinase inhibitor
原文传递
导出
摘要 布格替尼(brigatinib)是第2代间变性淋巴瘤激酶(ALK)酪氨酸激酶抑制剂,通过抑制ALK自身磷酸化和ALK-介导的下游信号蛋白STAT3、AKT、ERK1/2,以及S6在体外和体内的磷酸化,而表现出对4种EML4-ALK的突变体形式的体内抗肿瘤活性。对间变性淋巴瘤激酶转移性非小细胞肺癌(NSCLC)患者有显著疗效。美国食品与药品管理局于2017年4月批准布格替尼上市,本文以布格替尼为关键词进行文献检索,并对其作用机制、药动学、临床评价、用法用量、药物相互作用及安全性等进行综述。 Brigatinib is a second-generation anaplastic lymphoma kinase(ALK) tyrosine kinase inhibitor(TKI). It shows anti-tumor activity of4 kinds of EML4-ALK mutant forms by inhibiting the phosphorylation of ALK and ALK-mediated downstream signaling proteins, STAT3, AKT,ERK1/2. also by inhibiting the phosphorylation of S 6 in vitro and in vivo. It shows a significant curative effect of the anaplastic lymphoma kinase(ALK+) metastatic non-small cell lung cancer(NSCLC) patients. FDA approved brigatinib in April 2017. After literature search for brigatinib with keywords,the mechanism of action, pharmacokinetics, clinical evaluation, dosage, drug interactions, and safety of brigatinibwere reviewed
作者 杨雪 倪倩 裴艺芳 封宇飞 YANG Xue;NI Qian;PEI Yi-fang;FENG Yu-fei(Department of Pharmacy,Beijing Hospital,National Center of Gerontology,Assessment of Clinical Drugs Risk and Individual Application Key Laboratory,Beijing 100730,China)
出处 《临床药物治疗杂志》 2018年第6期32-36,共5页 Clinical Medication Journal
关键词 布格替尼 间变性淋巴瘤激酶酪氨酸激酶抑制剂 非小细胞肺癌 转移性 药理作用 临床评价 brigatinib anaplastic lymphoma kinase tyrosine kinase inhibitor (ALK-TKI) non-small cell lung cancer (NSCLC) metastatic phar-macological clinical evaluation
  • 引文网络
  • 相关文献

参考文献1

二级参考文献41

  • 1WHO. Globoean 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 [EB/OL]. [2015437-06]. http :// globocan, iarc. fr/Pages/online, aspx.
  • 2Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer [J]. Nature, 2007, 448(7153):561-566.
  • 3Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS [J]. Cancer, 2009, 115(8) :1723-1733.
  • 4Shackelford RE, Vora M, Mayhall K, et al. ALK-rearrangements and testing methods in non-small cell lung cancer : a review [J]. Genes Cancer, 2014, 5(1-2):1-14.
  • 5Vidal J, Clav S, de Muga S, et al. Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patients[J]. J Thorac Oneol, 2014, 9(12):1816-1820.
  • 6Pan Y, Zhang Y, Li Y, et al. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features[J]. Lung Cancer, 2014, 84 (2) : 121-126.
  • 7Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer[J]. N Engl J Med, 2014, 370 ( 13 ) : 1189-1197.
  • 8Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer [J]. N Engl J Med, 2014, 371 (23) :2167-2177.
  • 9Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer[J]. N Engl J Med, 2013, 368(25):2385-2394.
  • 10Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROSl-rearranged non-small-cell lung cancer[J]. N Engl J Med, 2014, 371 (21) : 1963-1971.

共引文献29

同被引文献32

引证文献4

二级引证文献9

;
使用帮助 返回顶部